Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Blue Trust Inc.

Blue Trust Inc. reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 6.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,740 shares of the biopharmaceutical company’s stock after selling 949 shares during the period. Blue Trust Inc.’s holdings in Bristol-Myers Squibb were worth $745,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of BMY. Westside Investment Management Inc. raised its stake in shares of Bristol-Myers Squibb by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock valued at $367,000 after acquiring an additional 204 shares during the period. Traynor Capital Management Inc. increased its holdings in Bristol-Myers Squibb by 2.8% in the 1st quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 207 shares during the last quarter. Fulton Breakefield Broenniman LLC raised its position in Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 209 shares during the period. Chapin Davis Inc. lifted its stake in Bristol-Myers Squibb by 1.2% during the fourth quarter. Chapin Davis Inc. now owns 18,385 shares of the biopharmaceutical company’s stock worth $943,000 after purchasing an additional 214 shares in the last quarter. Finally, Accurate Wealth Management LLC boosted its position in shares of Bristol-Myers Squibb by 4.0% during the first quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock worth $304,000 after buying an additional 216 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $0.20 during mid-day trading on Friday, hitting $39.66. 12,824,373 shares of the stock were exchanged, compared to its average volume of 15,346,125. The stock’s fifty day simple moving average is $42.27 and its two-hundred day simple moving average is $47.78. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $65.38. The stock has a market capitalization of $80.39 billion, a price-to-earnings ratio of -12.79, a P/E/G ratio of 13.71 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. On average, analysts forecast that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 6.05%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BMY. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 27th. Barclays reduced their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. BMO Capital Markets reduced their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Finally, Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.